Gedeon Richter has announced that their biosimilar for osteoporosis, Teriparatide, is to be made available on the NHS for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. As a result, the NHS can now provide an additional option for the treatment of osteoporosis in this subset of patients.
The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that would include biosimilars in the scope of its price controls. The statutory scheme covers those companies who don’t sign on to the voluntary Pharmaceutical Price Regulation Scheme (PPRS). To coincide with the new PPRS scheme, expected to come into